In Brief: Immunex' Leukine
Immunex' Leukine: Supplemental PLAs for chemotherapy-induced neutropenia and use in acute myelogenous leukemia will be reviewed by FDA's Biological Response Modifiers Advisory Committee "in early April," Immunex announces March 13. FDA tentatively has set a meeting date for the committee of April 10-11. FDA requested more information on the clinical data submitted for the GM-CSF product sargramostim, the company says; "based on the questions received and discussions with the FDA to date, the company believes these questions and comments can be addressed without posing a significant delay in the review process"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth